[Alpha Biz=(Chicago) Reporter Kim Jisun] Donghwa Pharmaceutical announced on the 18th that it will acquire rights in nine regions in the Asia-Pacific region of the four best-selling general medicine (OTC) sold by Celltrion.
The acquisition targets are the comprehensive cold medicine Whitetoben, the blood donation drug "Whitetoben Nasal Spray," the stomatitis treatment Albothyl, and the vitamin D and calcium supplements "Calcichew." The target areas are Thailand, Taiwan, Hong Kong, Macau, the Philippines, Singapore, Malaysia and Australia, including South Korea.
Even after the acquisition of the rights of Donghwa Pharmaceutical Co., Shinshin Pharmaceutical Co. will continue to be in charge of domestic sales of these products until 2025 under domestic supply contracts such as White2ben and Albochil signed by Shinshin Pharmaceutical Co. with Celltrion Pharmaceutical Co. in 2022.
Celltrion has launched a plan to sell its "Primary Care" business in the Asia-Pacific region, which it acquired from Takeda in 2020.
With this acquisition, Donghwa Pharmaceutical plans to enter the pill-type cold medicine market through Huituven and the stomatitis treatment market through Albochil in addition to the liquid-type general cold medicine 'Pancol'. It also explains that it expects overall OTC sales growth through this acquisition.
Alphabiz Reporter Kim Jisun(stockmk2020@alphabiz.co.kr)
